# Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY)

> **NCT02452736** · PHASE3 · COMPLETED · sponsor: **Medtronic Vascular** · enrollment: 205 (actual)

## Conditions studied

- Ischemic Heart Disease
- Cardiovascular Diseases
- Arteriosclerosis
- Coronary Artery Disease

## Interventions

- **DEVICE:** Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System

## Key facts

- **NCT ID:** NCT02452736
- **Lead sponsor:** Medtronic Vascular
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2015-08
- **Final completion:** 2015-12
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2016-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02452736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02452736, "Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02452736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*